Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2001 2
2002 3
2003 4
2004 2
2005 6
2006 8
2007 9
2008 9
2009 6
2010 9
2011 3
2012 2
2013 12
2014 10
2015 8
2016 11
2017 15
2018 10
2019 13
2020 19
2021 36
2022 19
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

192 results
Results by year
Filters applied: . Clear all
Page 1
Therapeutic drug monitoring of oral targeted antineoplastic drugs.
Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, Jaehde U, Steeghs N, Huitema ADR, Kloft C. Mueller-Schoell A, et al. Among authors: kloft c. Eur J Clin Pharmacol. 2021 Apr;77(4):441-464. doi: 10.1007/s00228-020-03014-8. Epub 2020 Nov 9. Eur J Clin Pharmacol. 2021. PMID: 33165648 Free PMC article. Review.
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Berlak M, Tucker E, Dorel M, Winkler A, McGearey A, Rodriguez-Fos E, da Costa BM, Barker K, Fyle E, Calton E, Eising S, Ober K, Hughes D, Koutroumanidou E, Carter P, Stankunaite R, Proszek P, Jain N, Rosswog C, Dorado-Garcia H, Molenaar JJ, Hubank M, Barone G, Anderson J, Lang P, Deubzer HE, Künkele A, Fischer M, Eggert A, Kloft C, Henssen AG, Boettcher M, Hertwig F, Blüthgen N, Chesler L, Schulte JH. Berlak M, et al. Among authors: kloft c. Mol Cancer. 2022 Jun 10;21(1):126. doi: 10.1186/s12943-022-01583-z. Mol Cancer. 2022. PMID: 35689207 Free PMC article.
[Medication safety in hospitals].
Sleinitz A, Heyde C, Kloft C. Sleinitz A, et al. Among authors: kloft c. Med Monatsschr Pharm. 2012 Apr;35(4):140-51. Med Monatsschr Pharm. 2012. PMID: 22582518 Review. German.
Role of TDM-based dose adjustments for taxane anticancer drugs.
Muth M, Ojara FW, Kloft C, Joerger M. Muth M, et al. Among authors: kloft c. Br J Clin Pharmacol. 2021 Feb;87(2):306-316. doi: 10.1111/bcp.14678. Epub 2020 Dec 18. Br J Clin Pharmacol. 2021. PMID: 33247980 Free article. Review.
[Bleeding caused by Ginkgo biloba extract?].
Kloft C, Kellermann A. Kloft C, et al. Pharm Unserer Zeit. 2009;38(5):440-6. doi: 10.1002/pauz.200900332. Pharm Unserer Zeit. 2009. PMID: 19711320 Review. German. No abstract available.
Pharmacokinetic/pharmacodynamic modelling in oncological drug development.
Karlsson MO, Anehall T, Friberg LE, Henningsson A, Kloft C, Sandström M, Xie R. Karlsson MO, et al. Among authors: kloft c. Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):206-11. doi: 10.1111/j.1742-7843.2005.pto960310.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 15733216 Free article. Review.
Safety of therapeutic monoclonal antibodies.
Niebecker R, Kloft C. Niebecker R, et al. Among authors: kloft c. Curr Drug Saf. 2010 Oct;5(4):275-86. doi: 10.2174/157488610792246055. Curr Drug Saf. 2010. PMID: 20615177 Review.
192 results